收藏切换
Meta-analysis of adverse drug reactions of crizotinib in the treatment of ALK positive non-small cell lung cancer
收藏切换
Le KANG1, Yan WANG1, Qi FANG1, Mudan HE2, *
World Clinical Drug | 2024, 45(10) : 1091 - 1098
Less
收藏切换
World Clinical Drug | 2024, 45(10): 1091-1098
• Article •
Meta-analysis of adverse drug reactions of crizotinib in the treatment of ALK positive non-small cell lung cancer
Full
Le KANG1, Yan WANG1, Qi FANG1, Mudan HE2, *
Affiliations
  • 1.Pharmaceutical preparation section, Wusong Hospital of Baoshan District, Shanghai 201900, China
  • 2.Department of Respiratory, Wusong Hospital of Baoshan District, Shanghai 201900, China
Published: 2024-10-10 doi: 10.13683/j.wph.2024.10.015
Outline
收藏切换
Objective

To conduct a meta-analysis of the adverse drug reactions (ADR) caused by crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).

Methods

Literature on randomized controlled trials of crizotinib in the treatment of ALK-positive NSCLC published in domestic and foreign databases from the establishment of the database to August 2023 were searched. RevMan 5.4 software was used for meta-analysis.

Results

A total of 8 literatures were included, including 2 058 subjects (998 patients in crizotinib test group and 1 060 patients in chemotherapy or other targeted control group), and the quality of the included literatures was good. The overall incidence of ADR (≥grade 3) in test groups was lower than that in control group [RR=0.67, 95% confidence interval (CI): 0.46~0.96, P=0.03]. The incidence of leukopenia, neutrophils and thrombocytopenia (<grade 3) in test group was lower than that in other targeted groups (RR=0.71, 95%CI: 0.55~0.92, P=0.01). The incidence of upper respiratory tract infection (≥grade 3) and liver enzyme elevation (<grade 3) in test group was lower than that in chemotherapy group (RR=0.10, 95%CI: 0.01~0.95, P=0.04; RR=0.84, 95%CI: 0.74~0.94, P=0.004). The incidence of liver enzyme elevation in test group (≥grade 3) was higher than that in chemotherapy group (RR=2.13, 95%CI: 1.14~3.97, P=0.02).

Conclusion

Crizotinib has good overall safety and low blood system adverse reactions in the treatment of ALK-positive NSCLC. However, the liver function should be closely monitored to avoid the occurrence of adverse reactions of ≥grade 3 liver enzymes elevation.

crizotinib  /  non-small cell lung cancer  /  adverse drug reactions  /  meta analysis
康乐, 王彦, 方琦, 何牡丹. 克唑替尼治疗ALK阳性非小细胞肺癌致药品不良反应的meta分析. 世界临床药物, 2024 , 45 (10) : 1091 -1098 . DOI: 10.13683/j.wph.2024.10.015
Le KANG, Yan WANG, Qi FANG, Mudan HE. Meta-analysis of adverse drug reactions of crizotinib in the treatment of ALK positive non-small cell lung cancer[J]. World Clinical Drug, 2024 , 45 (10) : 1091 -1098 . DOI: 10.13683/j.wph.2024.10.015
Year 2024 volume 45 Issue 10
14
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.10.015
  • Receive Date:2023-07-12
  • Online Date:2026-11-17
  • Published:2024-10-10
Article Data
Affiliations
History
  • Received:2023-07-12
Funding
Affiliations
    1.Pharmaceutical preparation section, Wusong Hospital of Baoshan District, Shanghai 201900, China
    2.Department of Respiratory, Wusong Hospital of Baoshan District, Shanghai 201900, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.10.015
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT